Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4) for new non‑executive employees. On January 31, 2026, the Compensation Committee granted restricted stock awards to seven hires covering up to 28,676 restricted shares.
One‑third of each award vests annually on each anniversary of the grant date, with full vesting on the third anniversary, subject to continued employment.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Inducement grants | Neutral | +1.7% | Inducement restricted stock awards totaling 79,584 shares to seven hires. |
| Dec 15 | Executive appointment | Positive | -5.2% | Appointment of Mohamad Tabrizi as Senior Vice President, Chief Business Officer. |
| Dec 11 | Commercial expansion | Positive | +0.9% | UTMB in Texas activated as Qualified Treatment Center for ZEVASKYN. |
| Dec 08 | First patient treated | Positive | +5.3% | First commercial patient treatment with FDA‑approved ZEVASKYN gene therapy. |
| Dec 01 | Inducement grants | Neutral | -5.7% | Inducement restricted stock awards covering 45,685 shares to two new hires. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Routine operational and commercialization updates, including prior inducement grants, have tended to produce modest, mixed price reactions, with both gains and declines following similar announcements.
Over the past few months, Abeona reported several milestones, including new inducement equity grants on Dec 1 and Dec 31, 2025, a new Qualified Treatment Center for ZEVASKYN on Dec 11, the first commercial patient treatment on Dec 8, and a senior leadership appointment on Dec 15. Price reactions ranged from about -5.7% to +5.3%, indicating that even routine or operational news can coincide with notable short‑term volatility.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
restricted stock awards financial
grant date technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On January 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 28,676 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com